Search

Purpose: To report spontaneous closure of a tractional Stage III macular hole (MH) in a patient with proliferative diabetic retinopathy (PDR) after panretinal photocoagulation (PRP). Methods: Case report of a 43-year-old man with poorly controlled Type I diabetes and bilateral severe proliferative diabetic retinopathy. Results: On presentation, visual acuity was 20/400 and fundus examination was significant for a Stage III tractional MH in the left eye. Vision in the right eye was light perception from neovascular glaucoma. Fluorescein angiography showed extremely severe macular and peripheral ischemia, disk neovascularization, and macular traction from fibroglial tissue. After 5 panretinal photocoagulation sessions over 3 months, the MH spontaneously closed; however, vision remained 20/400. Fluorescein angiography showed regressed disk neovascularization and mild diffuse macular leakage. After a 13-month loss to follow-up, he presented with 20/300 vision, and, despite extensive macular traction from fibroglial tissue, the MH remained closed. Owing to progressive traction from the fibroglial tissue, macular retinal detachment occurred and vision decreased to hand motions. The patient underwent pars plana vitrectomy, scar tissue removal, silicone oil tamponade, and laser. Postoperatively, visual acuity decreased to no light perception because of neovascular glaucoma complications and lack of proper follow-up. Conclusion: Spontaneous closure of a Stage III MH may occur in patients with PDR after PRP; however, it may not result in long-term visual improvement. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate alterations in treatment burden and course of exudative age-related macular degeneration in patients who contracted endophthalmitis from intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections., Methods: Retrospective study at the University of Pittsburgh Medical Center examining frequency of anti-VEGF injections, activity of choroidal neovascularization, and visual acuity before and after endophthalmitis treatment., Results: Twenty-one patients meeting inclusion criteria were identified, of whom 7 (33%) patients did not restart anti-VEGF treatment 12 months after endophthalmitis because of quiescence of exudative age-related macular degeneration without significant visual acuity loss (P > 0.05). Patients who resumed anti-VEGF treatment exhibited 32% and 38% decreases in injection frequency by 12 and 24 months after endophthalmitis, respectively (P < 0.05). On first optical coherence tomography follow-up, 10 patients exhibited quiescence of choroidal neovascularization activity, although there were no measurable changes in macular thickness (P > 0.05). No differences in post-endophthalmitis exudative age-related macular degeneration progression or treatment burden were observed when factoring adjuvant intravitreal steroid therapy, culture results, nor choroidal neovascularization subtypes., Conclusion: Endophthalmitis resolution is associated with a decrease in choroidal neovascularization activity and a reduction of anti-VEGF treatment burden in patients with exudative age-related macular degeneration.